Showing 5371-5380 of 5689 results for "".
- Glaukos: Study Confirms Long-Term Efficacy and Safety Profile of iStent in Combination with Cataract Surgeryhttps://modernod.com/news/study-confirms-long-term-efficacy-and-safety-profile-of-glaukos-istent-in-combination-with-cataract-surgery/2476375/Glaukos announced that results of an international glaucoma study published in the Journal of Cataract and Refractive Surgery showed use of iStent Trabecular Micro-Bypass Stent during cataract surgery delivered a 38% reduction in mean IOP to 14.7 mmHg after 5 years of follow-up. The
- Dompé Receives Industry Innovation Award for Oxervate Eye Drops for Neurotrophic Keratitishttps://modernod.com/news/dompe-receives-industry-innovation-award-for-oxervate-eye-drops-for-neurotrophic-keratitis/2476372/Dompé Farmaceutici S.p.A and Dompé US Inc. announced that the National Organization for Rare Disorders (NORD) has awarded them the 2019 Industry Innovation Award for Oxervate. The Rare Impact Awards celebrate people, organizations, and innovators making exceptional contributions benefiting rare d
- ProQR Reports First Patient Dosing in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2https://modernod.com/news/proqr-reports-first-patient-dosing-in-phase-1-2-stellar-trial-of-qr-421a-for-usher-syndrome-type-2/2476365/ProQR Therapeutics announced the first patient dosed in the phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP). Interim data from the study are expected to be announced mid-2019. “There are no effective treat
- Study Results Show NeurOptics’ NPi-200 Pupillometer Provides Early Warning of Neurological Damagehttps://modernod.com/news/study-results-show-neuroptics-npi-200-pupillometer-provides-early-warning-of-neurological-damage/2476358/A new study found that NeurOptics’ NPi-200 Pupillometer, which provides an automated assessment of the pupillary light reflex, may signal an early warning of potential delayed cerebral ischemia and enable preemptive escalation of care. The study was published in the Journal of Neurosurgery
- Roche/Genentech Initiate Two Large Phase 3 Studies in Wet AMD for Bispecific Molecule, Faricimabhttps://modernod.com/news/roche-genentech-initiate-two-large-phase-3-studies-in-wet-amd-for-bispecific-molecule-faricimab/2476355/Roche and Genentech have initiated two large global phase 3 clinical trials in wet age-related macular degeneration (AMD) investigating the bispecific molecule, faricimab. Faricimab is the first bispecific antibody designed specifically for the treatment of retinal eye diseases that simultaneousl
- Eyecare Services Partners Names New CEO and Adds Two Other Executiveshttps://modernod.com/news/eyecare-services-partners-names-new-ceo-and-adds-two-other-executives/2476353/Eyecare Services Partners (ESP) has appointed George Neal as chief executive officer, effective March 4. Mr. Neal was previously chief executive officer of Access Dental, a dental services organization that was recently sold by Guardian Life Insurance Company of America, according to a
- New Laser Helps Doctors Image Full Eye in 3Dhttps://modernod.com/news/new-laser-helps-doctors-image-full-eye-in-3d/2476348/Scientists have developed a laser-based technique that can produce a full 3D image of all the layers of the retina, allowing doctors to better diagnose and treat eye diseases such as cataracts, diabetic retinopathy, and cancer, according to an Octlight news release. Researchers from the Te
- Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophyhttps://modernod.com/news/apellis-resumes-dosing-in-its-phase-3-program-for-patients-with-geographic-atrophy/2479589/Apellis Pharmaceuticals announced that it has resumed enrollment in its two phase 3 GA trials (DERBY & OAKS) with intravitreal APL-2 for the treatment of geographic atrophy (GA). In October 2018, Apellis
- Aldeyra Therapeutics Provides Update on Ophthalmic Programshttps://modernod.com/news/aldeyra-therapeutics-provides-update-on-ophthalmic-programs/2476256/Aldeyra Therapeutics updated progress on ophthalmic programs at a 2019 Research & Development Day in New York City. Presentations were given by members of the Aldeyra executive team along with Dean Eliott, MD, the Stelios Evangel
- TopiVert Announces First Patients Dosed in THEIA-1 Phase 2b/3 Study of Dry Eye Disease Treatmenthttps://modernod.com/news/topivert-announces-first-patients-dosed-in-theia-1-phase-2b-3-study-of-dry-eye-disease-treatment/2476259/TopiVert Pharma announced that the first patients have been dosed in the THEIA-1 phase 2b/3 clinical study evaluating TOP1630, a novel anti-inflammatory kinase inhibitor, as an ophthalmic solution for the treatment of dry eye disease. THEIA-1 is a multicenter, randomised, double-masked, pl